RxDoctor Payments Data

Vincent Deorchis, MD

Neurology · New Hyde Park, NYNPI 1396995916

Payments from drug & device makers

$54,550in general payments, 2019–2025

Across 993 payments — averaging $54.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$31K
  • Ceribell, Inc.$9K
  • Biogen$1K
  • Amgen$1K
  • Pfizer$1K
  • Neurocrine Biosciences, Inc.$873
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$8,79516%
  • Speaking & faculty fees$27,52550%
  • Travel & lodging$2901%
  • Food & beverage$17,87033%
  • Education$690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie154$30,740
Ceribell, Inc.7$8,795
Biogen101$1,276
Amgen(2 entities)53$1,061
Pfizer66$1,002
Neurocrine Biosciences, Inc.51$873
SK Life Science, Inc.63$813
EMD Serono, Inc.37$729
AstraZeneca(2 entities)35$698
Takeda Pharmaceuticals U.S.A., Inc.23$656
Eisai Inc.20$611
Lundbeck LLC53$594
Grifols USA, LLC20$472
Acadia Pharmaceuticals Inc34$450
Lilly USA, LLC24$434
Genentech USA, Inc.13$355
Impel Pharmaceuticals Inc.14$314
Biohaven Pharmaceuticals, Inc.8$294
Scilex Pharmaceuticals Inc.19$265
Biohaven Pharmaceutical Holding Company Ltd.14$263
Sanofi13$243
Kyowa Kirin, Inc.9$220
Corium, LLC17$218
Teva Pharmaceuticals USA, Inc.12$217
Amneal Pharmaceuticals LLC8$182
Amylyx Pharmaceuticals, Inc.5$179
UCB, Inc.8$156
Johnson & Johnson2$150
CSL Behring7$144
Otsuka America Pharmaceutical, Inc.7$143
Novartis12$131
Medtronic3$129
Mallinckrodt Hospital Products Inc.7$127
Balt USA, LLC1$115
Neurelis, Inc.4$114
Bristol Myers Squibb7$113
Argenx US, Inc.4$112
Stryker2$109
Ipsen Biopharmaceuticals, Inc4$96
Acorda Therapeutics, Inc6$92
Tanabe Pharma America, Inc.4$78
MDD US Operations, LLC4$69
Zyla Life Sciences, Inc.3$51
Sunovion Pharmaceuticals Inc.3$51
Supernus Pharmaceuticals, Inc.3$49
Merz Pharmaceuticals, LLC2$48
Upsher-smith Laboratories LLC3$45
GE HealthCare1$42
Banner Life Sciences, LLC2$39
Alnylam Pharmaceuticals Inc.2$34
Octapharma USA, Inc.2$34
Axsome Therapeutics, Inc.1$32
Vanda Pharmaceuticals Inc.2$32
Boston Scientific1$28
Vertex1$27
Avanir Pharmaceuticals, Inc.1$25
Assertio Therapeutics, Inc.2$24
Xeris Pharmaceuticals, Inc.1$22
Strongbridge US Inc.1$21
Azurity Pharmaceuticals, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,550 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$389,096
Medicare patients
1,198
Services billed
3,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate65$119,497
Gamunex-CImmune Globul G/Gly/Iga Avg 4617$119,266
UbrelvyUbrogepant55$85,109
Droxidopa19$66,666
QuliptaAtogepant28$39,849
OngentysOpicapone24$34,458
Rivastigmine68$16,155
Memantine Hcl ErMemantine Hcl53$14,880
Ajovy AutoinjectorFremanezumab-Vfrm18$13,571
NamzaricMemantine Hcl/Donepezil Hcl11$12,764
Pregabalin271$10,563
Aimovig AutoinjectorErenumab-Aooe11$8,063
Carbidopa-LevodopaCarbidopa/Levodopa208$7,364
Donepezil Hcl444$6,102
Lacosamide35$3,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Namzaric$30,740$137,72294 claims
PfizerNurtec Odt$1,002$119,49765 claims
Grifols USA, LLCGamunex-C$472$119,26617 claims
Neurocrine Biosciences, Inc.Ongentys$873$34,45824 claims
Upsher-smith Laboratories LLCTopiramate$45$12724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →